Literature DB >> 404216

Second trial drugs in ovarian cancer.

C R Stanhope, J P Smith, F Rutledge.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 404216     DOI： 10.1016/0090-8258(77)90007-5

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  9 in total

Review 1.  Drug therapy for gynaecological cancer in older women.

Authors:  R E van Rijswijk; J B Vermorken
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

Review 2.  Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors:  R M Canetta; S K Carter
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

3.  Human tumor clonogenic assays. An overview.

Authors:  B I Sikic; R L Taber
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

4.  Phase II trial of vinblastine in advanced ovarian carcinoma. A Gynecologic Oncology Group study.

Authors:  G P Sutton; J A Blessing; M D Adelson; P Hanjani
Journal:  Invest New Drugs       Date:  1990-11       Impact factor: 3.850

5.  Chemotherapy of ovarian cancer directed by the human tumor stem cell assay.

Authors:  D S Alberts; H S Chen; S E Salmon; E A Surwit; L Young; T E Moon; F L Meyskens
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

6.  Activity of tricyclic nucleoside 5'-phosphate in model systems of human ovarian cancer.

Authors:  B C Behrens; T C Hamilton; K G Louie; K R Grotzinger; W M McKoy; T Tsuruo; R C Young; R F Ozols
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

7.  [Effective treatment of peritoneal carcinosis by intraperitoneal cis-diamminedichloroplatinum (c-DDP) administration with systemic sodium thiosulfate protection. Clinical results and pharmacokinetics].

Authors:  H Rückle; G Ehninger; F Jakob; K Wilms
Journal:  Klin Wochenschr       Date:  1986-05-15

Review 8.  Intraperitoneal therapy in the management of ovarian carcinoma.

Authors:  M Markman; T Hakes; B Reichman; W Hoskins; S Rubin; W Jones; L Almadones; J L Lewis
Journal:  Yale J Biol Med       Date:  1989 Jul-Aug

9.  Cisplatin/carboplatin cross-resistance in ovarian cancer.

Authors:  M E Gore; I Fryatt; E Wiltshaw; T Dawson; B A Robinson; A H Calvert
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.